1010 Background: High TMB correlates with high neoantigen burden, and this is thought to be predictive of response to immunotherapy. The aim of this work is to evaluate frequency, mutational patterns, and genomic profile of hypermutated breast cancer. Methods: We used sequencing data from publically available on cbioportal.org, including TCGA, France 2016, MSK-IMPACT, MBCProject, AACR-GENIE, and ongoing studies at our institute (The Center for Cancer Precision Medicine Metastatic Breast Cancer Study; The Young Women’s Breast Cancer Study) to evaluate mutational load across breast cancers. Samples were classified as having high TMB if they had > 10 mutations (mut) per megabase (MB). Results: We included 3689 samples for the analysis. The median TMB was 1.55 mut/MB. TMB significantly varied according to histology (ductal > lobular, p= 4.6x10-13), tumor subtype (HR-/ HER2+ > TNBC > HR+/HER2+ > HR+/HER2-, p < 0.05), staging (metastatic > primary, p= 2.2x10-16) and site of metastasis (higher soft tissue, and lowest lung, p < 0.05). We found a total of 70 (~2%) hypermutated tumors (62.8% metastatic vs 37.2% primary samples). Mutational signature analysis of the hypermutated samples showed the presence of dominant APOBEC (77.1%), homologous recombination (HR; 2.9%), defective DNA mismatch repair (MMR; 18.6%), and POLE hypermutation (1.4%) signatures. Median TMB was higher for samples with POLE and HR signature, followed by those with MMR and APOBEC (93.1, 38.7, 14.6 and 12.4 mut/MB, respectively). Among hypermutated tumors, 8 samples had somatic mutation in the POLE gene, but only the case with POLE signature high had a characterized POLE driver mutation. In addition, 80% of hypermutated tumors with APOBEC signature had PIK3CA mutations versus 31% of hypermutated tumors with other signatures (p = 0.0005). Conclusions: TMB is correlated with clinical parameters including histology, receptor subtype and site of metastasis. Different mutational signatures are present in this population, including POLE, defective DNA MMR, HR and APOBEC. The potential role of these different signatures in predicting benefit to immunotherapy in hypermutated breast cancers is unclear, and warrants further investigation.